BioTuesdays

Category - Markets

Leap Therapeutics
Markets

HCW cuts Leap Therapeutics PT to $3.25 from $7.50

H.C. Wainwright lowered its price target for Leap Therapeutics (NASDAQ:LPTX) to $3.25 from $7.50 after the company decided to re-allocate resources and focus on advancing DKN-01, its anti-Dickkopf-1 antibody, while...

November 15, 2019
Genocea Biosciences
Markets

SVB Leerink starts Genocea Biosciences at OP; PT $7

SVB Leerink launched coverage of Genocea Biosciences (NASDAQ:GNCA) with an “outperform” rating and price target of $7. The stock closed at $2.24 on Nov. 14. “Our positive view is based on the promise of Genocea’s ATLAS...

November 15, 2019
Liminal BioSciences
Markets

Liminal BioSciences to begin trading on NASDAQ

Common shares of Liminal BioSciences (TSX:LMNL; OTCQX:PFSCF) were approved for trading on the Nasdaq Global Market, effective Nov. 18, under the ticker symbol, LMNL. The shares will continue to trade on the Toronto...

November 15, 2019
Motus GI Holdings
Markets

AGP cuts PT for Motus GI to $3.75 from $6

Alliance Global Partners lowered its price target for Motus GI Holdings (NASDAQ:MOTS) to $3.75 from $6, reflecting a lower sales multiple and reduced estimates after the company’s third quarter report. The stock closed...

November 15, 2019
Arvinas
Markets

Roth starts Arvinas at buy; PT $35

Roth Capital Partners initiated coverage of Arvinas (NASDAQ:ARVN) with a “buy” rating and $35 price target. The stock closed at $28.38 on Nov. 13. Analyst Zegbeh Jallah writes that Arvinas is one of the leaders in the...

November 14, 2019
GlycoMimetics
Markets

Roth resumes coverage of GlycoMimetics at buy; PT $12

Roth Capital Partners resumed coverage of GlycoMimetics (NASDAQ:GLYC) with a “buy” rating and price target of $12. The stock closed at $6.26 on Nov. 13. Analyst Zegbeh Jallah writes that following an August announcement...

November 14, 2019
Bicycle Therapeutics Logo
Markets

Roth starts Bicycle Therapeutics at buy; PT $17

Roth Capital Partners launched coverage of Bicycle Therapeutics (NASDAQ:BCYC) with a “buy” rating and $17 price target. The stock closed at $8.61 on Nov. 13. Bicycle is developing peptides that may be able to deliver a...

November 14, 2019
Harpoon Therapeutics
Markets

Roth starts Harpoon Therapeutics at buy; PT $25

Roth Capital Partners launched coverage of Harpoon Therapeutics (NASDAQ:HARP) with a “buy” rating and price target of $25. The stock closed at $13.51 on Nov. 13. Analyst Zegbeh Jallah writes that Harpoon has a next...

November 14, 2019